by Comite Web | Nov 15, 2022
The HUF pancreatic cancer group is currently participating in the TRIPP-FFX trial: FOLFIRINOX versus OncoSil™ in addition to FOLFIRINOX for patients with locally advanced pancreatic adenocarcinoma. This is an open-label, multicenter, randomized trial of intratumoral targeted therapy of P-32 (OncoSil™) associated with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in patients with unresectable locally advanced pancreatic adenocarcinoma. The purpose of the study is to evaluate the safety and efficacy of OncoSil™ when administered in addition to standard FOLFIRINOX chemotherapy for the treatment of locally advanced pancreatic cancer.
by Comite Web | Nov 15, 2022
VigPanc is a recently formed multidisciplinary group born from our dedication to care, research and intellectual interest in the study and treatment of pancreatic tumors. We are witnessing every day the difficulty in its diagnosis and subsequent management, as well as its associated morbidity. Moreover, the current available treatments are insufficient, despite recent improvements, both from a professional and social point of view.
In Galicia, we have an incidence rate of pancreatic cancer of 22 per 100,000 inhabitants, with a total of 604 new cases in 2022, according to the AECC cancer observatory. In our Medical Oncology service at the Álvaro Cunqueiro Hospital, we had 56 first consultations of patients diagnosed with pancreatic cancer in 2022, a figure that is increasing every year.
In short, we intend to be a group with a clear vocation for translational research, born from the multidisciplinary meetings that are held weekly in our center and that have allowed us to discuss the real problems of our patients across specialties, as well as the interdisciplinary interaction mainly for care purposes, but increasingly with more interest for research purposes and to provide practical knowledge about this disease.
Lines:
- Clinical: analysis of symptoms and signs present in pancreatic cancer, as well as the identification of prognostic factors for the evolution of the disease.
- Treatments: Participation in clinical trials. Search for predictive factors of response.
- Molecular biology and translational research: search for diagnostic, prognostic and predictive biomarkers of treatment response. Study of tissue biopsies and/or liquid biopsy. Use of multi-omics data, NGS and bioinformatics.
- Prognostic factors of complications in pancreatic surgery. Multimodal rehabilitation
by Comite Web | Nov 15, 2022
This group includes two teams that carry out their research at the Hospital del Mar:
The group of “Ablation therapies in oncologic surgery“directed by Fernando BurdíoThe primary objective of the scientific production and technological innovation in the field of applications of high frequency currents in the generation of heat in biological tissues, aimed at local cell destruction, minimally invasiveof pathological tissues, especially (but not exclusively) of human neoplasms.
https://www.imim.cat/programesrecerca/cancer/es_thipertermia.html
The “Molecular Targets of Cancer” group led by Pilar Navarro (IIBB-CSIC/ Associated Unit Hospital del Mar Research Institute (HMRI)) has been exploring the molecular mechanisms of pancreatic cancer for more than 20 years with the aim of identifying new targets to improve early diagnosis and treatment of this tumor. For this purpose, we use cell and molecular biology techniques, in vitro functional assays and preclinical animal models that recapitulate the human pancreatic tumor and its microenvironment.
Our most recent studies are focused on Galectin-1. as a biomarker and new therapeutic immune checkpoint (Martínez-Bosch N et al. Oncotarget 2018; Martínez-Bosch N et al. Cancer Res. 2014; Orozco CA et al. PNAS 2018; Navarro P et al. Clin Cancer Res. 2020), sAXL as an early biomarker of pancreatic cancer and differential diagnosis of chronic pancreatitis (Martínez-Bosch N et al. eBioMed 2022) and the study of translational control as a new mechanism of gene reprogramming in this cancer (Ortiz-Zapater E et al. Nat Med. 2012; Villanueva E et al. Nat Comm. 2017; Jungfleisch J et al. Genome Res. 2017).
